Showing papers by "Kunzer Aaron R published in 2015"
Patent•
09 Dec 2015TL;DR: In this paper, small molecule Bcl-xL inhibitors and antibody drug conjugates (ADCs) are disclosed for the treatment of diseases that involve a dysregulated apoptosis pathway.
Abstract: Small molecule Bcl-xL inhibitorsand Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl xL proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway.
12 citations
Patent•
09 Dec 2015TL;DR: In this article, the authors discuss Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions of the inhibitors or ADCs and various methods of using the inhibitors and ADCs.
Abstract: The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.
7 citations
Patent•
09 Dec 2015TL;DR: In this article, small molecule Bcl-xL inhibitors and antibody drug conjugates (ADCs) are disclosed for the treatment of diseases that involve a dysregulated apoptosis pathway.
Abstract: Small molecule Bcl-xL inhibitors and Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl xL proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway.
6 citations
Patent•
09 Dec 2015
TL;DR: In this paper, a presente invention concerne des inhibiteurs de Bcl-xL ayant une faible permeabilite cellulaire, des conjugues anticorps-medicament (ADC) comprenant les inhibiteur, des synthons utiles pour la synthese des ADC, and divers procedes d'utilisation des inhibititeurs and des ADC.
Abstract: La presente invention concerne des inhibiteurs de Bcl-xL ayant une faible permeabilite cellulaire, des conjugues anticorps-medicament (ADC) comprenant les inhibiteurs, des synthons utiles pour la synthese des ADC, des compositions comportant les inhibiteurs ou les ADC, et divers procedes d'utilisation des inhibiteurs et des ADC.
Patent•
09 Dec 2015
TL;DR: The authors concerne des inhibiteurs de Bcl-xl a petites molecules and des conjugues anticorps-medicament (ADC) comprenant les inhibiteur de BCL-xL a petite molecules.
Abstract: La presente invention concerne des inhibiteurs de Bcl-xL a petites molecules et des conjugues anticorps-medicament (ADC) comprenant les inhibiteurs de Bcl-xL a petites molecules. Les inhibiteurs de Bcl-xL et les ADC de l'invention sont utiles, entre autres, pour l'inhibition de proteines anti-apoptotiques Bcl-xL en tant qu'approche therapeutique pour le traitement de maladies qui impliquent une voie de l'apoptose deregulee.
Patent•
15 Sep 2015TL;DR: In this article, compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-APOPotic BCL-2 protein.
Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
Patent•
09 Dec 2015
TL;DR: The presente invention concerne des inhibiteurs de Bcl-xL inhibitors a petite molecule and des conjugues anticorps-medicament comprenant des inhibititeurs Bcl xL inhibitors as mentioned in this paper.
Abstract: La presente invention concerne des inhibiteurs de Bcl-xL inhibiteurs a petite molecule et des conjugues anticorps-medicament comprenant des inhibiteurs Bcl-xL a petite molecule. Les inhibiteurs de Bcl-xL et les conjugues anticorps-medicament de l'invention sont utiles notamment pour l'inhibition de proteines Bcl xL anti-apoptotiques en tant qu'approche therapeutique vers le traitement de maladies qui impliquent une voie de l'apoptose deregulee.